期刊文献+

沃诺拉赞的全球专利现状分析 被引量:4

Analysis of the patents of vonoprazan on the world current situation
原文传递
导出
摘要 为了帮助国内制药企业全面了解沃诺拉赞的相关专利现状,指引后续技术研发和产品的市场布局方向,增加市场竞争力。本文运用专利情报分析方法,依据检索所得的国内外沃诺拉赞相关技术的专利数据,对沃诺拉赞相关专利的申请趋势、技术生命周期、专利区域分布状况、重要申请人、专利技术主题、技术发展路线以及国内专利法律状态等因素进行了分析,并重点结合技术主题分析以及技术发展路线,明确了沃诺拉赞技术的研发热点以及空白点。通过上述专利分析,国内企业可以根据自身研发计划以及市场规划,提早进行专利战略布局,找准突破口,为抢占市场做好准备。 In order to help the domestic pharmaceutical companies to understand the relevant patents of vonoprazan,guide the follow-up technology research and the direction of product market,and enhance market competitiveness. This paper analyzes application trends of the vonoprazan related patent,technical life cycle,the distribution of patent regional status,important applicants,patented technology theme,technology development route,the legal status of domestic patent and other factors. The paper also clear up the hot spots and blank spots of vonoprazan technology research and development focus on the technical theme analysis and technology development line. Through the above patent analysis,domestic enterprises can complete the strategic layout,identify the breakthrough and get ready to seize the market according to their own RD programs and market planning.
出处 《中国新药杂志》 CAS CSCD 北大核心 2018年第3期273-278,共6页 Chinese Journal of New Drugs
关键词 沃诺拉赞 专利分析 vonoprazan patent analysis
  • 相关文献

参考文献2

二级参考文献49

  • 1马维野.切实抓好源头 促进目的实现[J].中国发明与专利,2008(12):8-9. 被引量:3
  • 2杨莉,李野.关于中药专利保护特殊规则的探讨[J].中国药房,2006,17(10):728-730. 被引量:10
  • 3Shin J M, Sachs G. Long lasting inhibitors of the gastric H, K-ATPase[J]. Expert Rev Clin Phamlacol. 2009, 2 (5): 461-468.
  • 4Sifrim D, Zerbib F. Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors [J].Gut, 2012, 61 (9): 1340-1354.
  • 5Dellon E S, Gonsalves N, Hirano I, et al. ACG clinical guideline: evidenced based approach to the diagnosis and management of esophageal eosinophilia and eosinophilic esophagitis (EoE) [J]. Am J Gastlventerol, 2013, 108 (5): 679-692.
  • 6Chiba T, Malferthciner P, Satoh H. Proton pump inhibitors: a balanced view [J]. lndianJ MedRes, 2015, 142 (3): 352.
  • 7Shin J M, Kim N. Pharmacokinetics and phannacodynamics of the proton pump inhibitors[J]. J Neumgastroentetvl Motil, 2013, 19 ( 1): 25-35.
  • 8Wang Y K. Hsu W H, Wang S S, et al. Current pharmacological management of gastroesophageal reflux disease [J]. GastJventero/Res Pratt, 2013, 2013 ( 1): 983653-983665.
  • 9Devault K R, Yalley N J. Insights into the future of gastric acid suppression[J]. Nat Rev Gastroenterol tfepatol, 2()09, 6 (9): 524 532.
  • 10Agarwal V, Bansal M. Statistical optimization and fabrication of a press coated pulsatilc dosage r11 to treat nocturnal acid breakthrough [J]. Curt Drug De/iv, 2013, 10 (4): 444-452.

共引文献37

同被引文献13

引证文献4

二级引证文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部